| sunitinib / Generic mfg. |
NCT00979381: Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor |
|
|
| Completed | N/A | 75 | Europe | influenza vaccine | Radboud University Medical Center | Renal Cell Carcinoma, GIST | 11/08 | 11/09 | | |
NCT01246843: Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib |
|
|
| Completed | N/A | 50 | Europe | | Radboud University Medical Center | Metastatic Renal Cell Cancer, GIST | 04/11 | 04/11 | | |
NCT00976612: Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK |
|
|
| Completed | N/A | 17 | RoW | Nilotinib | Asan Medical Center | Gastrointestinal Stromal Tumors | 08/11 | 12/11 | | |
NCT00094029 / 2004-001860-27: A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248 |
|
|
| Approved for marketing | N/A | | US, Canada, Europe, RoW | Sutent | Pfizer | Gastrointestinal Neoplasm | 10/11 | 10/11 | | |
NCT00979329: Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST |
|
|
| Completed | N/A | 100 | Europe | Questionnaires | Radboud University Medical Center | Renal Cell Cancer, Colorectal Cancer, GIST | 12/11 | 12/15 | | |
NCT01459757: Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib |
|
|
| Completed | N/A | 322 | US, Canada, Europe, RoW | non-interventional | Pfizer | GIST | 04/13 | 04/13 | | |
| Completed | N/A | 223 | Canada, US, Europe, RoW | sunitinib | Pfizer | Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer, Non-Small Cell Lung Cancer, Thyroid Cancer, Advanced/Metastatic Non-Small Cell Lung Cancer, Advanced Gastric Cancer, Gastrointestinal Stromal Tumor, Hepatocellular Carcinoma, Pancreatic Islet Cell Carcinoma, Pancreatic Neuroendocrine Tumor | 08/14 | 09/14 | | |
NCT01054911: Evaluation of Patients With Bulky GIST Using Sunitinib |
|
|
| Terminated | N/A | 5 | US | Sunitinib, SUTENT (Sunitinib), Surgery | University of Alabama at Birmingham, Pfizer | Tumor | 09/14 | 09/15 | | |
NCT01646593: Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy |
|
|
| No Longer Available | N/A | | US | Regorafenib (BAY73-4506) | Bayer | Gastrointestinal Stromal Tumors | | | | |
NCT00444795: Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene |
|
|
| Completed | N/A | 520 | RoW | Sunitinib malate, sunitinib malate | Pfizer | Gastrointestinal Stromal Tumors | 03/15 | 03/15 | | |
NCT00716820: Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan). |
|
|
| Completed | N/A | 472 | NA | SUNITINIB MALATE, SUTENT | Pfizer | Gastrointestinal Stromal Tumors | 10/15 | 09/16 | | |
NCT01689376: Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program) |
|
|
| No Longer Available | N/A | | RoW | Regorafenib (BAY73-4506) | Bayer | Gastrointestinal Stromal Tumors | | | | |
NCT03424876: To Compare the Efficacy of Surgery Followed by Sunitinib With Surgery Followed by Imatinib in GIST Patients With Progression on Imatinib. |
|
|
| Unknown status | N/A | 60 | RoW | Imatinib 400mg, Sunitinib 37.5Mg Oral Capsule | Peking University | GIST | 06/18 | 08/18 | | |
NCT03880617: Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy |
|
|
| Completed | N/A | 297 | RoW | | National Taiwan University Hospital | CML, GIST | 08/20 | 08/20 | | |
NCT03862768: Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment |
|
|
| Unknown status | N/A | 92 | NA | surgery, Imatinib 400 MG, Imatinib escalation, Sunitinib | Shanghai Zhongshan Hospital | Gastrointestinal Stromal Tumors, Surgery | 06/21 | 12/21 | | |
STAR-TOR, NCT00700258: Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [] |
|
|
| Completed | N/A | 1520 | Europe | Temsirolimus, Sunitinib, Axitinib | Pfizer | Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors | 12/21 | 12/21 | | |
|
|
|
|
|
ChiCTR2000029913: Role of surgery in patients with focally progressive GISTs after imatinib treatment: a prospective, multicenter, registration study |
|
|
| Recruiting | N/A | 122 | | Surgery + Imatinib400mg/d ;imatinib 600mg/d or sunitinib 37.5mg/d | Zhongshan Hospital affiliated to Fudan University; Zhongshan hospital affiliated to fudan university, National natural science foundation of China (81773080) | Gastrointestinal stromal tumor | | | | |
NCT05381753: Safety and Efficacy of Avapritinib in Chinese Patients with Gastrointestinal Stromal Tumor (GIST) in the Real World |
|
|
| Active, not recruiting | N/A | 60 | RoW | Avapritinib, Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al ) | CStone Pharmaceuticals | Gastrointestinal Stromal Tumors | 05/25 | 10/25 | | |
NCT05751733: Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST |
|
|
| Recruiting | N/A | 258 | RoW | Apatinib Mesylate, Sunitinib, Imatinib dosage, Dasatinib, Reveratinib | Xiangya Hospital of Central South University, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Gastrointestinal Stromal Tumors | 01/26 | 01/27 | | |
| Recruiting | N/A | 330 | Europe | Blood sampling to build population pharmacokinetics model | UNICANCER | Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma, GIST, Neuroendocrine Tumors | 08/26 | 06/27 | | |
